Ombrabulin
 | |
| Names | |
|---|---|
| IUPAC name
(2S)-2-Amino-3-hydroxy-N-[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide | |
| Other names
AVE-8062; AVE-8062A; AC7700; CS-39-L-Ser.HCl | |
| Identifiers | |
181816-48-8  253426-24-3 (HCl) | |
| ChemSpider | 5293602  |
| |
| Jmol-3D images | Image |
| PubChem | 6918405 6918404 (HCl) |
| |
| Properties | |
| Molecular formula |
C21H26N2O6 |
| Molar mass | 402.44 g·mol−1 |
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| verify (what is: /?) | |
| Infobox references | |
Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis.[1] Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.[2][3] It was granted orphan drug status by the European Medicines Agency in April 2011.[4] In January 2013, Sanofi said it discontinued development of ombrabulin after disappointing results from phase III clinical trials.[5]
References
- ↑ "Ombrabulin (AVE8062)". Sanofi-Aventis Oncology.
- ↑ Hori, K; Saito, S; Nihei, Y; Suzuki, M; Sato, Y (1999). "Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700". Japanese journal of cancer research : Gann 90 (9): 1026–38. doi:10.1111/j.1349-7006.1999.tb00851.x. PMID 10551334.
- ↑ Hori, K; Saito, S; Kubota, K (2002). "A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs". British journal of cancer 86 (10): 1604–14. doi:10.1038/sj.bjc.6600296. PMC 2746587. PMID 12085211.
- ↑ "Orphan Designation EU/3/11/853". European Medicines Agency. 15 April 2011.
- ↑ "Sanofi has 65 new compounds in development, says R&D chief".